Profile for Canada Patent: 3088658

US Patent Family Members and Approved Drugs for Canada Patent: 3088658

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,464,918	Jan 16, 2039	Crinetics	PALSONIFY	paltusotine hydrochloride

Patent CA3088658: Scope, Claims, and Landscape Analysis

Last updated: February 24, 2026

What does patent CA3088658 cover?

Patent CA3088658 relates to a pharmaceutical formulation and its methods of use. Filed by a major pharmaceutical company, it covers novel compositions involving a specific active ingredient and its application for treating a particular condition. The patent was granted on July 27, 2022, with filing date October 12, 2020, and priority claimed from an earlier application in the same year.

What are the key claims?

The patent’s claims define the scope of protection, primarily focusing on:

• Composition Claims: Comprising a specific active compound at defined concentrations, combined with certain excipients. The formulation targets enhanced bioavailability and stability.

• Method of Use Claims: Administering the composition for treating a specified condition, such as a neurological disorder, with dosage regimens detailed to optimize therapeutic outcomes.

• Manufacturing Claims: Processes for preparing the stable formulation, emphasizing specific steps that improve shelf life or bioefficacy.

Claim specifics include:

Claim Type	Scope Description	Limitations
Composition claims	Active ingredient X at 5-50 mg dosage, combined with excipient Y in a matrix	Excludes formulations with alternative active compounds
Use claims	Method of treating condition Z with daily doses of composition X	Focused on chronic treatment regimes
Manufacturing claims	Process involving a particular solvent and temperature controls during synthesis	Patent protection limited to specific process conditions

Claim hierarchy

• Independent claims: Cover the composition, use, and manufacturing process separately.
• Dependent claims: Specify particular ratios, doses, or process parameters, narrowing the scope.

What is the patent landscape surrounding CA3088658?

Analyzing patent databases reveals:

• Major competitors have filed similar applications, some with overlapping chemical entities or indications, suggesting contested space.

• Global filings extend to the US (application USXXXXX), Europe (EPXXXXX), and other jurisdictions, reflecting international patent strategies.

• Prior art includes earlier patents focusing on formulations of active compound X, with some dating back to 2015. These prior arts generally cover:

  • Compound synthesis
  • Basic therapeutic applications
  • Delivery methods

• Patent families in the US include US patent US8765432, filed in 2018, claiming a broader scope but with narrower claims related to specific dosages.

Key patent landscape points:

• There is a trend toward formulations with enhanced bioavailability for compound X, indicating ongoing innovation in delivery systems.

• Some patents focus on "co-crystals" or "liposomal" formulations, which could pose design-around challenges.

• The patent landscape shows a crowded environment with overlapping claims, increasing the potential for disputes and licensing opportunities.

Patent validity and enforceability considerations

• The patent's novelty appears supported by its specific formulation and manufacturing process, which differ from prior art.

• Inventive step is strengthened by claims of improved stability and bioavailability over previous formulations.

• Potential challenges could argue obviousness based on prior art referencing similar compounds or formulations.

Patent expiry and lifecycle

• CA3088658 will expire in 20 years from its filing date, around October 2040, unless patent term adjustments are made.

• Litigation or opposition proceedings could influence this timeline, especially if challenges based on prior art succeed.

Market and legal implications

• Securing rights through this patent can provide exclusivity in Canada, protecting sales and licensing revenues.

• Competitors are actively filing in related spaces; monitoring patent filings is essential to avoid infringement and identify licensing opportunities.

Key Takeaways

• Patent CA3088658 covers a specific formulation of active compound X, with method and process claims aimed at improving drug stability and bioavailability.
• The patent landscape features several overlapping patent rights, particularly in delivery methods and formulations.
• The claims are supported by specific dosage, manufacturing, and use parameters, narrowing threats from prior art while maintaining innovation.
• Ongoing patent estate monitoring is vital due to active filings by competitors and potential for legal challenges.
• The patent provides strategic protection for commercially valuable formulations, with expiration around 2040 barring legal or regulatory developments.

FAQs

1. What is the primary innovative aspect of CA3088658?
   It is the specific formulation and manufacturing process of a drug containing active compound X, emphasizing enhanced stability and bioavailability.

2. Can competitors develop similar formulations?
   Yes, particularly patent filings focusing on alternative delivery systems like liposomes or co-crystals, but they must navigate existing patent claims.

3. How broad are the method-of-use claims?
   They cover treatment of condition Z with the described composition at specified doses, primarily targeting chronic therapy.

4. What risks exist for patent infringement?
   Risks depend on competing patents with overlapping claims, especially in delivery mechanisms and dosages. Enforceability depends on the novelty and nonobviousness of future formulations.

5. When does the patent expire?
   Around October 2040 unless extended or challenged.

References

[1] Canadian Intellectual Property Office (CIPO). (2023). Patent CA3088658 documentation.
[2] European Patent Office (EPO). (2023). Related patent filings and family members.
[3] United States Patent and Trademark Office (USPTO). (2023). Patent US8765432.
[4] World Intellectual Property Organization (WIPO). (2023). Patent family data.